Fig. 4: ICV infusion of ART5803 reverses abnormal behaviors induced by pathogenic autoantibody (#003-102 Ab) in marmoset disease model.

a Experimental design of ART5803 intracerebroventricular (ICV) infusion efficacy study. Continuous ICV infusion of pathogenic #003-102 Ab (10 µg/h) into the third ventricle in marmosets for 4 weeks. Two weeks after ICV infusion of #003-102 Ab, continuous ICV infusion of ART5803 (n = 9) or control antibody (n = 3) at 10 µg/h was administered alongside the ICV infusion of #003-102 Ab for an additional 2 weeks. Over the course of the study, abnormal behaviors were evaluated using the abnormal rating scale. b Time course of abnormal behaviors (Abnormal Rating Scale, maximum score 22) in marmosets with ART5803 ICV infusion at Day 0, Day 14, and Day 28. Each point is from an individual marmoset (n = 9) and bars represent mean ± SEM. Statistical analysis was performed between timepoints using two-tailed, Wilcoxon matched-pairs signed rank test. **, p < 0.01. c Comparison of abnormal behaviors between ART5803 and control antibody ICV-infused groups at Day 0, Day 14 and Day 28 of the study. Each point is from an individual marmoset and data are mean ± SEM of n = 3 (#003-102 Ab + Control antibody) or n = 9 (#003-102 Ab + ART5803). Statistical analysis was performed using unpaired, two-tailed, Student’s t-tests. *, p < 0.05; ns = not significant. Source data are provided in Supplementary Table S5.